Objectives: To determine the in vitro activities and interactions of imipenem, colistin and tigecycline with old antibacterial agents against carbapenem-resistant Acinetobacter baumannii.
Introduction
Acinetobacter baumannii has emerged as one of the most important nosocomial pathogens, especially in patients admitted to an intensive care unit (ICU). A. baumannii can colonize multiple body sites of hospitalized patients and survive for a long time on inanimate surfaces. 1, 2 Both these aforementioned characteristics may have contributed to the prominent role of A. baumannii in nosocomial infections.
Fluoroquinolones, ceftazidime, trimethoprim/sulfamethoxazole and carbapenems have been considered active against nosocomial A. baumannii strains. However, treatment of this organism has become a medical challenge because of the emergence of multidrug-resistant isolates, including resistance to carbapenems, with increasing frequency. 3, 4 Therefore, new agents or combination regimens of old agents known to be effective against multidrug-resistant A. baumannii are attracting more attention. Meropenem/sulbactam combinations have shown synergistic effects in multidrug-resistant strains of A. baumannii. 5, 6 An old drug, colistin, which was abandoned since the 1960s due to nephrotoxicity, gained new interest for its activity against A. baumannii and one study, although small in sample size, showed a good outcome with a combination regimen of colistin and rifampicin. 7, 8 Tigecycline showed good in vitro bacteriostatic activity against A. baumannii strains that showed different susceptibilities to imipenem. 
Materials and methods
Forty-three clinical isolates of carbapenem-resistant A. baumannii were collected from routine clinical isolates from patients admitted to the ICU during the period of January 2002 to June 2006. Isolates were selected randomly from different patients.
For the 43 isolates, MICs of imipenem, colistin (colistimate sodium), tigecycline, sulbactam and rifampicin were determined by a broth microdilution method in Mueller -Hinton broth by geometric 2-fold serial dilutions. According to CLSI (formerly NCCLS) standards, strains were considered resistant to carbapenems if the MICs of imipenem were !32 mg/L. 10 The following concentrations were considered as the susceptibility breakpoints of other tested antimicrobials: colistin, 4 mg/L; tigecycline, 4 mg/L; sulbactam, 8 mg/L; rifampicin, 2 mg/L.
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In vitro bactericidal activities and synergistic effects were evaluated using time-kill assays. Eight imipenem-resistant isolates were randomly selected from the 43 clinical isolates.
Aliquots of A. baumannii strains were cultured at 358C in tubes containing Trypticase soy broth, bacterial inoculum at an approximate size of 10 5 cfu/mL and antibiotics to be tested. The concentrations used for colistin and tigecycline were 1Â, 4Â and 8Â MIC. For the evaluation of synergistic effects, imipenem and sulbactam were combined at 1Â MIC each and colistin and rifampicin at 1Â MIC each. At 0, 4, 8 and 24 h of incubation at 358C, aliquots of 100 mL were obtained from each tube and 10-fold dilutions were made and cultured on Trypticase soy agar plates for 24 h at 358C. The number of colonies formed was counted. Bactericidal activity was defined as a 3 log 10 decrease in cfu/mL, and synergy was defined as a !2 log 10 decrease in cfu/mL between the combination and its most active constituent.
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Antibiotic powders were obtained from their respective manufacturers: colistin methanesulphonate (X-gen Pharmaceuticals Inc., NY, USA), imipenem cilastatin (Choong-Wae Pharm, Seoul, Korea), sulbactam pivoxil (Keun-hwa Pharm, Seoul, Korea), tigecycline (Wyeth Co., MA, USA) and rifampicin (Donginbiotech Co, Seoul, Korea).
As for the above eight imipenem-resistant isolates, PCR was carried out to detect Ambler class B carbapenemase bla IMP-1 , bla IMP-2 , bla VIM-1 and bla VIM-2 and Ambler class D OXA-type carbapenemases. The primers used in this study are shown in Table 1 . Each reaction mixture (20 mL) contained 1 mL of genomic DNA, 10 pmol of each primer, 1 U of Taq DNA polymerase, 0.25 mM dNTP, 10 mM Tris-HCl ( pH 9.0), 40 mM KCl and 1.5 mM MgCl 2 . For Ambler class B carbapenemases, the mixture was heated to 948C for 5 min and then subjected to 30 cycles of 948C for 30 s, at each specific annealing temperature (Table 1) for 1 min and 728C for 1 min, followed by a final extension for 7 min at 728C. PCR reactions for OXA-type carbapenemases were carried out with heating to 948C for 5 min, followed by 30 cycles of 948C for 30 s, 528C for 40 s and 728C for 50 s, and final extension for 7 min at 728C.
Results
MICs of imipenem, colistin, tigecycline, sulbactam and rifampicin are shown in Table 2 . All the isolates were resistant to imipenem but susceptible to colistin and tigecycline.
In time -kill studies, colistin showed bactericidal activity against all carbapenem-resistant strains at 4Â and 8Â MIC concentrations, usually beginning at 8 h after inoculation (Table 3) . In comparison, tigecycline was not bactericidal, but showed good bacteriostatic activity against all carbapenem-resistant strains at any tested concentration (Table 4) .
According to the time-kill synergy results, the combination of imipenem and sulbactam, both at a concentration of 1Â MIC, appeared to be synergistic against most of the carbapenemresistant strains after 4 h, excluding the second strain which failed to show synergism ( Figure 1 ). Moreover, a bactericidal effect of imipenem/sulbactam was shown after 8 h. There was sustained synergistic inhibitory activity lasting for more than 24 h; bacterial colony counts were reduced by !2 log 10 cfu/mL when compared with imipenem alone. Likewise, the combination of colistin and rifampicin was synergistic and bactericidal with a mean decrease of 4.29 + 1.47 log 10 cfu/mL after 8 h (Figure 2 ). According to the PCR results for carbapenemases, the bla OXA-51 b-lactamase gene was detected in all eight strains, but PCR results for other OXA b-lactamase (OXA-23, -24 and -58) and Ambler class B carbapenemase (bla IMP-1 , bla IMP-2 , bla VIM-1 and bla VIM-2 ) genes were all negative.
Discussion
Nowadays, the rate of carbapenem resistance among nosocomial A. baumannii isolates is high, particularly in ICUs. Increasing rates of carbapenem resistance have led to widespread use of colistin for the treatment of diverse infectious disease due to A. baumannii. However, colistin-resistant A. baumannii has been reported recently, and heterogeneous colistin resistance among multidrug-resistant isolates has been reported. 14 Moreover, according to the results of this study, colistin showed a bactericidal effect only at a high concentration, above 4Â MIC, which is clinically important considering the dose-dependent nephrotoxicity of colistin. 15 Although some studies have reported clinical efficacy of colistin, the effects of combined antimicrobial agents or antimicrobial susceptibility were not considered in those studies. 16, 17 In contrast, Motaouakkil et al. 18 reported a favourable clinical response to a colistin-and rifampicincombined regimen against multidrug-resistant A. baumannii. Colistin is a concentration-dependent antimicrobial agent, and it is known to show only a modest post-antibiotic effect against A. baumannii at high concentrations. 15 In this study, we could see the synergistic and bactericidal effects of the colistin-and rifampicin-combined regimen just at the MIC level, which was sustained for !24 h.
Synergistic activity of imipenem and sulbactam against A. baumannii has been reported previously, and included two imipenem-resistant strains. 5 In the present study, we again showed the synergistic and bactericidal effects of this regimen even against carbapenem-resistant strains. This synergistic activity might be related to the concentration of bacterial penicillin-binding protein 2. 5 However, there is a chance that those effects can differ according to the resistance mechanisms; serine-b-lactamase, metallo-b-lactamase (IMP and VIM type), efflux pumps and outer membrane protein change. 19 Especially, VIM-2 b-lactamase in A. baumannii from Korea showed significantly high level resistance to carbapenem. Actually, the imipenem/sulbactam combination failed to show synergism against one of the carbapenem-resistant strains in this study, which had a higher MIC of imipenem (!64 mg/L) when compared with the strains. Likewise, colistin did not show a bactericidal effect in some strains (strains 1, 3, 5, 7 and 8) at 4Â and 8Â MIC concentrations after 4 h from bacterial inoculation. Although we could not find a difference in carbapenemase production among study strains, the therapeutic effectiveness of antibiotic regimens might differ according to the diverse mechanisms of antimicrobial resistance; further studies are required.
Regarding tigecycline, it is very active against Acinetobacter spp. (generally .90% susceptibility, with MIC ,8 mg/L).
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Previously, Pachon-Ibanez et al. 9 reported that tigecycline has good in vitro bacteriostatic activity against A. baumannii, including one imipenem-intermediate and one imipenem-resistant strain. Likewise in this study, tigecycline showed favourable bacteriostatic activity against all carbapenem-resistant strains even at the MIC level, which was sustained for more than 24 h. Although tigecycline has not been registered in many countries yet, it is thought to be clinically useful, having good tissue penetration. Tigecycline-based combination regimens are expected to be investigated and applied clinically.
In conclusion, imipenem/sulbactam combination, colistin and tigecycline showed good in vitro activities against carbapenemresistant A. baumannii isolates. Even though colistin is bactericidal against carbapenem-resistant Acinetobacter spp., the colistin/ rifampicin combination is more warranted in order to be certain.
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